SK chemicals

2019: World's first trivalent and quadrivalent cell culture-derived influenza vaccines (Approved by WHO PQ); World's second varicella (chickenpox) vaccine (Approved by WHO PQ)

2018: SK bioscience starts phase 1 clinical trials in the U.S. for the next generation pneumococcal vaccine with Sanofi Pasteur; SK plasma opens new Andong plant; Spun off from the vaccine business sector, “SK bioscience” launched; “SKY Varicella Inj.,” obtains chickenpox vaccine obtained marketing approval; SK petrochemical merger

▲ Launched SK discovery, a holding company

2017: Launched SK discovery, a holding company; “Skyzoster,” shingles vaccine was approved for the second time in the world and for the first time in Korea; Received IR52 Jang Young-sil Award for biocopolyester / ABS composite material for automobile interior materials; Signed joint development and production contract for next-generation rotavirus vaccine with PATH, an international NPO organization; Expanded operation of PETG No. 3; SKYFLEX acquired product certification (DNV-GL) for wind power; The first application of automobile PCT connector in domestic large and mid-sized automobiles; AFSTYLA, hemophilia treatment drug approved in Europe, Australia (April), Japan for the first time for a new domestic bio drug

2016: Launched “SKYCellflu Quadrivalent,” the world's first quadrivalent cell-culture influenza vaccine; DMT production facility expansion (Capa-up); AFSTYLA, hemophilia treatment drug approved to be marketed in the U.S. and Canada (December) for the first time for a new domestic bio drug; Estabilished Dongtan Plastics Processing Resaerch Lab.; Developed high-performance secondary battery electrolyte additive for the first time in Korea

▲ Launched “SKYCellflu Quadrivalent,” the world's first quadrivalent cell -culture influenza vaccine

2015: World's first approved cell-culture quadrivalent influenza vaccine item; #1 in 2015 DJSI Korea Chemical sector; Hemophilia treatment NBP601 - US (FDA), EU (EMA) application for marketing approval; Launched “SKYCellflu®,” Korea's first cell-culture influenza vaccine; Division of blood product business and establishment of SK plasma, a subsidiary

2014: Won the Presidential Citation for Job Creation Merit Government Award; Awarded the 2014 K Pharma Night Innovative Pharmaceutical Company Award; Global Standard Management Award (Grand Prize in sustainability report sector); Signed PPS supply and joint marketing contract with Initz and A. Schulman; Acquired L HOUSE KGMP; Signed contract for development and supply of Sanofi Pasteur and next-generation pneumonia vaccine; Ansan Plant integrated with S House

▲ Signed contract for development and supply of Sanofi Pasteur and next-generation pneumonia vaccine

2013: Awarded the Minister Award and selected as Korea's Top 10 New Technologies in PCT material; Acquired L HOUSE LEED certification GOLD grade (first among global pharmaceutical plants); Establishment of Teijin and Initz, a joint venture, and construction of PPS facility; SKYGREEN acquired Korea's first “Gold Level” certification

2012: Hemophilia treatment, NBP601 selected as Korea's Top 10 New Technologies / won Ministry of Knowledge Economy Award; SID710 EU, patch type dementia treatment, entered the EU market

▲ Groundbreaking ceremony for Andong L House, a state-of-the-art vaccine factory

2011: Launched the world's first film-type erectile dysfunction treatment “Mvix S®”; Won Grand Prize in Green Management sector of the Global Standard Management Award; New Pangyo headquarters, Eco Lab Green Building certification (LEED Platinum certification) / Won Korean Architectural Culture Award; Groundbreaking ceremony for Andong L House, a state-of-the-art vaccine factory; CDP Special Award

2010: Biodiesel Green Technology Grand Prize Minister Award; Acquisition of shares and merger with SK NJC investment company

ESG 메뉴